

Press Release

June 1, 2021

Management exercise all warrants within the framework of the 2018 incentive program

2cureX AB ("2cureX") hereby announces that **Managing Director of 2cureX GmbH Jürgen Kupper** and **Chief Business Officer Maarten van der Linden** have chosen to use their rights to subscribe for shares in 2cureX AB by fully exercising the respective number of warrants in the warrant programs 2018/2020 and 2018/2021.

The now finalized warrant program for Jürgen Kupper and Maarten van der Linden included 103,400 and 84,600, respectively. The program was established shortly after 2cureX's listing at Nasdaq First North in 2018 for the two members of the management team. The total exercise price of the warrants amounts to SEK 1.6 million.

Jürgen Kupper has sold 35,600 2cureX shares on May 28th and 31st, 2021 to finance the purchase of the remaining warrants and to cover the capital gains tax in Germany.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer

E-mail: fa@2curex.com

Telephone: +45 2279 5399

www.2curex.com

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient's tumor and identifies the approved cancer treatment that most effectively kills the patient's tumor. Immediately after the test, the patient is given the selected treatment.

The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com. Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se.